Business Wire

 Domain Security Blind Spots Put Global Enterprises at Serious Risk According to New Research from CSC’s Digital Brand Services Division

16.6.2020 15:00:00 EEST | Business Wire | Press release

Share

CSC, a world leader in business, legal, tax, and domain security, today released its 2020 Domain Security Report: Forbes Global 2000 Companies from their Digital Brand Services (DBS) division. The report highlights significant shortfalls in enterprise domain security practices, putting organizations’ internet-facing digital assets at risk to threats, including domain name and domain name system (DNS) hijacking, phishing, and other fraudulent activity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005062/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Key Findings from CSC's 2020 Domain Security Report.

According to the report, 83% of Global 2000 organizations have not adopted basic domain security measures such as registry lock, which puts them at risk for domain name hijacking. The report indicates a wide industry disparity in domain security maturity with information technology and media and entertainment industries more likely to embrace available security controls, while industries such as materials and real estate trail behind.

“These security shortfalls are the direct result of not executing proper domain security techniques. Domain security cannot be an afterthought, and there needs to be a conscious effort to make this an intentional and critical part of every company’s overall cyber security posture, especially as criminals evolve their attack methods,” says Mark Calandra, executive vice president for CSC DBS. “As companies move to more online business models, it’s essential to use defense-in-depth practices to proactively manage, secure, and defend the foundational internet-facing components of your digital brand presence.”

Additional highlights from the report include:

  • Four out of five Global 2000 companies are severely at risk and exposed to domain name and DNS hijacking due to a lack of registry locks. Unlocked domains are vulnerable to social engineering tactics, which can lead to unauthorized DNS changes and domain name hijacking.
  • 53% of the Forbes Global 2000 use retail-grade domain registrars, putting them at greater risk for phishing, social engineering, and attacks while complicating compliance demands. The management of the overall domain name portfolio by a reputable corporate registrar versus a retail registrar will make the adoption of domain security standards much easier to implement and monitor.
  • Only 20% of Global 2000 companies use enterprise-grade DNS hosting. Lack of DNS hosting redundancy and using non-enterprise-level DNS providers poses potential security threats like resiliency to distributed denial of service (DDoS) attacks, as well as down time, and revenue loss.
  • 97% of the Global 2000 don’t use DNS security extensions (DNSSEC), which means the majority of companies are prone to cache poisoning attacks. Lack of deployment of DNSSEC leads to vulnerabilities in the DNS, which could include an attacker hijacking any step of the DNS lookup process.
  • Domain-based message authentication, reporting, and conformance (DMARC) use is only at 39% for the Global 2000 companies. DMARC is an email validation system designed to protect a company’s email domain from being used for email spoofing, phishing scams, and other cyber crime.

A core division of CSC, DBS is the trusted provider of choice for the Forbes Global 2000 and is the only enterprise-class registrar with a comprehensive set of solutions focused on defending businesses from targeted threat vectors to their domain names, DNS, and digital certificates. Moreover, the organization detects and mitigates online brand abuse, infringements, and fraud with the latest machine analysis and scoring technology to perform global enforcement, including takedowns and advanced techniques in internet blocking.

If you’re a member of SANS, to learn more, join CSC and SANS for a webinar Friday, June 19. Register here.

External links:

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christine Blake
W2 Communications
703-877-8114
CSC@w2comm.com
CSC® News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye